Funded by the Autoimmune Encephalitis Alliance, Inc. (AE Alliance)
Application Deadline: May 2, 2022
Award Notification: June 2022
The AE Alliance is pleased to announce the call for applications to our second annual AEA Community Seed grant program to support research focused on the diagnosis, management, and outcomes of individuals with autoimmune encephalitis (AE).
This year, multiple grants of $10,000-$30,000 will be awarded. Based on donation stipulations, at least one grant will be awarded to a project focused on seronegative AE. While applications pertaining to clinical, basic, and/or translational research will be considered, proposed studies must have direct implications for patients with AE.
Please submit all application documents (as PDFs) prior to the deadline by email to: email@example.com. Please include in the email the applicant’s full name, academic affiliation, and email address.
Review Process: Applications will be reviewed by the AE Alliance Special Grants Review Committee, which includes members of the Research Sub-Committee of the AE Alliance’s Medical Advisory Board. Applications will be scored based on their scientific rigor, impact, and alignment with the AE Alliance Mission (as noted above). Committee members with a potential conflict of interest with the applicant or project will recuse themselves from the review of that application. Following the review of all applications, the committee will make a recommendation to the Board of Directors of the AE Alliance, which will have the final approval for funding.
Meg Poe, Director of Patient Support, Programs and Administration
Our 2021 AEA Community Seed Grant Winners:
Development of optimal clinical approaches in seronegative autoimmune encephalitis
Soon-Tae Lee, MD, PhD – Seoul National University Hospital – South-Korea
Patient Reported Outcomes while Manipulating the Immune System in autoimmune Encephalitis
Juna de Vries, MD, PhD – Erasmus University – The Netherlands
Subclinical activity in anti-LGI1 encephalitis: diagnostic tests and prognostic implications
Amaia Muñoz Lopetegi, MD – Hospital Clinic of Barcelona – Spain